Therefore, we suggest that the efficacy of compound 23 against hematologic tumors may be related to the expression levels of ErbB2 and ErbB3 in hematologic tumor cells. The gene discussed is ERBB3; the disease is hematopoietic and lymphoid cell neoplasm.